| Basics |
Viking Therapeutics, Inc.
Viking Therapeutics Inc is a clinical-stage biopharmaceutical company. The company develops therapies for metabolic and endocrine disorders. It includes portfolio of five drug candidates in clinical trials or preclinical studies.
|
| IPO Date: |
April 29, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$3.05B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.42 | 3.38%
|
| Avg Daily Range (30 D): |
$0.67 | 2.54%
|
| Avg Daily Range (90 D): |
$0.92 | 3.34%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.67M |
| Avg Daily Volume (30 D): |
3.13M |
| Avg Daily Volume (90 D): |
3.95M |
| Trade Size |
| Avg Trade Size (Sh.): |
121 |
| Avg Trade Size (Sh.) (30 D): |
83 |
| Avg Trade Size (Sh.) (90 D): |
91 |
| Institutional Trades |
| Total Inst.Trades: |
3,871 |
| Avg Inst. Trade: |
$2.9M |
| Avg Inst. Trade (30 D): |
$3.02M |
| Avg Inst. Trade (90 D): |
$2.63M |
| Avg Inst. Trade Volume: |
.11M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$6.28M |
| Avg Closing Trade (30 D): |
$7.42M |
| Avg Closing Trade (90 D): |
$7.89M |
| Avg Closing Volume: |
248.55K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-1.15
|
$-.41
|
$-.32
|
|
Diluted EPS
|
$-1.15
|
$-.41
|
$-.32
|
|
Revenue
|
$ M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -128.24M
|
$ -45.63M
|
$ -35.42M
|
|
Operating Income / Loss
|
$ -172.32M
|
$ -55.47M
|
$ -46.24M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -157.54M
|
$ 11.26M
|
$ -23.6M
|
|
PE Ratio
|
|
|
|
|
